Taysha Gene Therapies, Inc. (TSHA) Profit Margins
Over the twelve months to 2026-06-30, Taysha Gene Therapies, Inc. (TSHA) had operating margin -2792.3%, net margin -2728.0%, free cash flow margin -2417.0%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TSHATaysha Gene Therapies, Inc.Follow TSHA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Gross margin | — | 93.1% | 41.9% | — | — | |
| Operating margin | -6492.7% | -468.8% | -1097.6% | -1130.6% | -2792.3% | |
| Net margin | -6635.3% | -722.1% | -1071.6% | -1115.3% | -2728.0% | |
| FCF margin | -4356.9% | -497.6% | -979.2% | -960.1% | -2417.0% |
USD millions · SEC XBRL
Taysha Gene Therapies, Inc. — questions
- What is Taysha Gene Therapies, Inc.'s operating margin?
- -2792.3% over the twelve months to 2026-06-30.
- What is Taysha Gene Therapies, Inc.'s net profit margin?
- -2728.0% over the twelve months to 2026-06-30.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.